WINT Stock Overview A biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Windtree Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Windtree Therapeutics Historical stock prices Current Share Price US$0.32 52 Week High US$14.75 52 Week Low US$0.29 Beta 0.57 1 Month Change -13.89% 3 Month Change -70.50% 1 Year Change -97.17% 3 Year Change -99.97% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates
Windtree Therapeutics, Inc. Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia Dec 10
Windtree Therapeutics Receives Multiple Nasdaq Deficiency Notices Dec 05 Windtree Therapeutics, Inc. announced delayed 10-Q filing Nov 16
Windtree Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective December 1, 2024 Nov 14
Windtree Therapeutics, Inc. Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong Nov 05
Windtree Therapeutics, Inc. Initiates Enrollment in the SEISMiC C Trial in SCAI Stage C Cardiogenic Shock Nov 02 See more updates
Windtree Therapeutics, Inc. Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia Dec 10
Windtree Therapeutics Receives Multiple Nasdaq Deficiency Notices Dec 05 Windtree Therapeutics, Inc. announced delayed 10-Q filing Nov 16
Windtree Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective December 1, 2024 Nov 14
Windtree Therapeutics, Inc. Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong Nov 05
Windtree Therapeutics, Inc. Initiates Enrollment in the SEISMiC C Trial in SCAI Stage C Cardiogenic Shock Nov 02
Windtree Therapeutics, Inc. Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock Oct 01
Windtree Announces Positive Topline Results from Its Phase 2B Seismic Extension Study of Istaroxime in Early Cardiogenic Shock Sep 25
Windtree Therapeutics, Inc. Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock Sep 04
Windtree Therapeutics, Inc., Annual General Meeting, Sep 24, 2024 Aug 22 Windtree Therapeutics, Inc. announced delayed 10-Q filing Windtree Therapeutics, Inc. announced that it has received $1 million in funding Jul 29
New major risk - Share price stability Jul 27 Windtree Therapeutics, Inc. has withdrawn its Follow-on Equity Offering. Jul 26
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data Jul 25 Windtree Therapeutics, Inc. announced that it has received $3.4 million in funding Jul 22
New major risk - Revenue and earnings growth Jul 09
Price target decreased by 89% to US$18.00 Jul 02 Windtree Therapeutics, Inc. has filed a Follow-on Equity Offering. May 10
Windtree Therapeutics Regains Compliance with Nasdaq May 09
Windtree Therapeutics Approves 1-for-18 Reverse Stock Split and Expects Compliance with Listing Requirements of the $1.00 Minimum Bid Price Requirement by The Nasdaq Capital Market Apr 19 Windtree Therapeutics, Inc. (NasdaqCM:WINT) acquired All of the assets of Varian Biopharmaceuticals, Inc. Windtree Therapeutics, Inc. announced delayed annual 10-K filing Apr 03
Windtree Therapeutics Receives Non-Compliance Notice from Nasdaq Jan 23
New major risk - Revenue and earnings growth Dec 28
Windtree Therapeutics, Inc. Announces the Start of Patient Dosing in Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock Dec 18 Windtree Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.054024 million. Nov 10
New major risk - Share price stability Oct 16
Windtree Therapeutics, Inc. Appoints Jamie McAndrew as Controller, Chief Accounting Officer and Principal Accounting Officer Aug 30
Windtree Therapeutics, Inc. Is Developing A Multi-Asset Franchise of Its Novel Serca2a Activators Aug 17
Windtree Therapeutics, Inc. Appoints Mark Strobeck to its Board of Directors Jun 28 Windtree Therapeutics, Inc. Announces Chief Financial Official Officer Changes
Nasdaq Grants Windtree Therapeutics 180-Day Extension to Regain Compliance Dec 06
Price target decreased to US$3.00 Nov 17
Windtree Therapeutics, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2022 Nov 15
Windtree Therapeutics, Inc. Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (Seismic) Published in the European Journal of Heart Failure Sep 29
Windtree Therapeutics, Inc. Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America Sep 27
Windtree Therapeutics, Inc. Reports Impairment for the Second Quarter Ended June 30, 2022 Aug 12
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value Jun 30
Windtree Therapeutics Receives Non-Compliance Letter from Nasdaq Jun 09
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid May 24
Windtree Therapeutics, Inc. Announces Not Stand for Re-Election of Evan Loh from Board May 13
Windtree Therapeutics, Inc., Annual General Meeting, Jun 07, 2022 May 12
Price target decreased to US$5.50 Apr 27
Windtree Therapeutics, Inc. Announces Positive Topline Results from Its Phase 2 Seismic Study of Istaroxime in Early Cardiogenic Shock Apr 21
Windtree Therapeutics Completes Enrollment in its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome Feb 02
Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video) Dec 06
Windtree Therapeutics, Inc. Announces Results of U.S. Hospital Claims Data Analysis Showing Hospital Inpatient Mortality and Length of Hospital Stay for Cardiogenic Shock Patients Nov 24
Independent Chairman of the Board recently bought US$95k worth of stock Oct 22
Price target decreased to US$8.25 Aug 25
Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions Jul 06
Independent Non-Executive Director Bruce Peacock has left the company Jun 19
Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable Jun 09
Independent Chairman of the Board recently bought US$354k worth of stock Apr 06
New 90-day low: US$4.94 Mar 03
Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)? Feb 09
Windtree Therapeutics, Inc. Announces Executive Changes Feb 05
Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development Feb 02
Windtree Therapeutics, Inc.(NasdaqCM:WINT) dropped from S&P TMI Index Jan 28
Windtree Therapeutics, Inc. Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19 Jan 08
New 90-day low: US$4.98 Dec 30
Windtree Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients Oct 02
Windtree Therapeutics, Inc. Announces FDA Acceptance of IND Application for a Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19 Sep 30
New 90-day low: US$5.94 Sep 29
Earnings released Aug 15
New 90-day high - US$9.90 Aug 04 Shareholder Returns WINT US Biotechs US Market 7D 2.8% 0.2% -0.2% 1Y -97.2% -4.7% 25.8%
See full shareholder returns
Return vs Industry: WINT underperformed the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: WINT underperformed the US Market which returned 25.8% over the past year.
Price Volatility Is WINT's price volatile compared to industry and market? WINT volatility WINT Average Weekly Movement 20.3% Biotechs Industry Average Movement 11.0% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: WINT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: WINT's weekly volatility has decreased from 30% to 20% over the past year, but is still higher than 75% of US stocks.
About the Company Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.
Show more Windtree Therapeutics, Inc. Fundamentals Summary How do Windtree Therapeutics's earnings and revenue compare to its market cap? WINT fundamental statistics Market cap US$2.86m Earnings (TTM ) -US$10.71m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) WINT income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$10.71m Earnings -US$10.71m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.19 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 10.1%
How did WINT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 07:54 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Windtree Therapeutics, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Vernon Bernardino H.C. Wainwright & Co. Andrew Fein H.C. Wainwright & Co. John Tanner Lazard Capital Markets
Show 6 more analysts 
